Matches in Nanopublications for { ?s ?p "[The depletion of B cells by anti-CD20/19 monoclonal antibody Retuximab� used in autoimmune diseases therapy leads to systemic side effects and should be significantly improved.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP650964.RAgVyCZnqx4vG941mkTb2bXM2yofbp1LYykjSZLssTE5M130_assertion description "[The depletion of B cells by anti-CD20/19 monoclonal antibody Retuximab� used in autoimmune diseases therapy leads to systemic side effects and should be significantly improved.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650964.RAgVyCZnqx4vG941mkTb2bXM2yofbp1LYykjSZLssTE5M130_provenance.
- NP911350.RAc6fUdYSXBCLfQ0R_HEWIIPNePatjH5620z4XZqtiv1o130_assertion description "[The depletion of B cells by anti-CD20/19 monoclonal antibody Retuximab� used in autoimmune diseases therapy leads to systemic side effects and should be significantly improved.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP911350.RAc6fUdYSXBCLfQ0R_HEWIIPNePatjH5620z4XZqtiv1o130_provenance.
- NP910996.RAdL2gcy5mr4yOhTSIsc6ezmPPzjjbMckf_kTBNLTfjb8130_assertion description "[The depletion of B cells by anti-CD20/19 monoclonal antibody Retuximab� used in autoimmune diseases therapy leads to systemic side effects and should be significantly improved.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP910996.RAdL2gcy5mr4yOhTSIsc6ezmPPzjjbMckf_kTBNLTfjb8130_provenance.
- NP290864.RABXVvp-gbNRasx4ULun7QtHBBo7rbWS3XDwGA9Xe_hxQ130_assertion description "[The depletion of B cells by anti-CD20/19 monoclonal antibody Retuximab� used in autoimmune diseases therapy leads to systemic side effects and should be significantly improved.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP290864.RABXVvp-gbNRasx4ULun7QtHBBo7rbWS3XDwGA9Xe_hxQ130_provenance.
- NP902454.RAorCHkcrPXzLeOfsJeEccRMm27Ssc-PG5JbKjRLAp4KE130_assertion description "[The depletion of B cells by anti-CD20/19 monoclonal antibody Retuximab� used in autoimmune diseases therapy leads to systemic side effects and should be significantly improved.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP902454.RAorCHkcrPXzLeOfsJeEccRMm27Ssc-PG5JbKjRLAp4KE130_provenance.
- NP902453.RAIxlHEi-zPyokLrAi-tOIC91w7cOuBMY7A54NAXgm1V8130_assertion description "[The depletion of B cells by anti-CD20/19 monoclonal antibody Retuximab� used in autoimmune diseases therapy leads to systemic side effects and should be significantly improved.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP902453.RAIxlHEi-zPyokLrAi-tOIC91w7cOuBMY7A54NAXgm1V8130_provenance.